Hexima

Follow
Get notifications in MyBN when activity occurs.
Subscribe to BN Log In

Hexima Limited (HXL) is a biotechnology company actively engaged in the research and development of plant-derived defensin peptides for applications as human therapeutics. Hexima's lead drug candidate is the plant defensin, pezadeftide (formerly HXP124), which is being developed for treatment of fungal nail infections (onychomycosis). Hexima is conducting a phase IIb clinical trial at 15 sites in Australia and New Zealand. The trial has enrolled 117 patients with onychomycosis and seeks to identify the optimal course of therapy for pezadeftide.

Contact Details

Level 4 , LIMS2, Kingsbury Dr LA TROBE UNIVERSITY VIC 3086
03 9479 1210
www.hexima.com.au

Lists and Charts

Share price

Hexima
Closing price for the last 90 trading days
View ASX Chart
Powered by Morningstar ®

Total Shareholder Return as at 02/12/24

Rank Company 1 Yr 5 Yr
1408th AnteoTech -43.23% 0.46%
1409th Clean Seas Seafood -43.32% -27.67%
1410th Hexima -43.48% 0%
1411th The Reject Shop -43.52% 8.95%
1412th Australian Vanadium -43.53% 3.45%
View Full List
1767 WA (and selected non WA) listed companies ranked by 1 year TSR relative to other companies with similar revenue
Powered by Morningstar ®

Company Share Transactions

20/03/24
Issued
Hexima
25/03/22
$48.42k Other
Hexima
24/02/22
$95.00k Other
Hexima
Total value as at the date of the transaction
Powered by Morningstar ®

    Related Information

    Access to our data for Hexima is only available to paid subscribers with Data & Insights access.

    Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

    Hexima is included in 1 list - Public Companies - non WA.

    For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

    Subscribe today

    X